Works matching IS 01676997 AND DT 2014 AND VI 32 AND IP 3

Results: 25

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.

Published in:

2014

By:

Necchi, A.;
Giannatempo, P.;
Mariani, L.;
Farè, E.;
Raggi, D.;
Pennati, M.;
Zaffaroni, N.;
Crippa, F.;
Marchianò, A.;
Nicolai, N.;
Maffezzini, M.;
Togliardi, E.;
Daidone, M.;
Gianni, A.;
Salvioni, R.;
Braud, F.

Publication type:

Journal Article

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.

Published in:

2014

By:

Goldwasser, Francois;
Faivre, Sandrine;
Alexandre, Jerome;
Coronado, Cinthya;
Fernández-García, Eva;
Kahatt, Carmen;
Paramio, Pilar;
Dios, Jorge;
Miguel-Lillo, Bernardo;
Raymond, Eric

Publication type:

Journal Article

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 452, doi. 10.1007/s10637-013-0047-4

By:

Dunbar, E.;
Coats, B.;
Shroads, A.;
Langaee, T.;
Lew, A.;
Forder, J.;
Shuster, J.;
Wagner, D.;
Stacpoole, P.

Publication type:

Article

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 481, doi. 10.1007/s10637-013-0055-4

By:

Devriese, Lot;
Koch, Kevin;
Mergui-Roelvink, Marja;
Matthys, Gemma;
Ma, Wen;
Robidoux, Andre;
Stephenson, Joe;
Chu, Quincy;
Orford, Keith;
Cartee, Leanne;
Botbyl, Jeff;
Arya, Nikita;
Schellens, Jan

Publication type:

Article

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 510, doi. 10.1007/s10637-013-0062-5

By:

Britten, Carolyn;
Adjei, Alex;
Millham, Robert;
Houk, Brett;
Borzillo, Gary;
Pierce, Kristen;
Wainberg, Zev;
LoRusso, Patricia

Publication type:

Article

Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 489, doi. 10.1007/s10637-013-0050-9

By:

Kelly, Kevin;
Shea, Thomas;
Goy, André;
Berdeja, Jesus;
Reeder, Craig;
McDonagh, Kevin;
Zhou, Xiaofei;
Danaee, Hadi;
Liu, Hua;
Ecsedy, Jeffrey;
Niu, Huifeng;
Benaim, Ely;
Padmanabhan Iyer, Swaminathan

Publication type:

Article

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 555, doi. 10.1007/s10637-014-0074-9

By:

Necchi, A.;
Giannatempo, P.;
Mariani, L.;
Farè, E.;
Raggi, D.;
Pennati, M.;
Zaffaroni, N.;
Crippa, F.;
Marchianò, A.;
Nicolai, N.;
Maffezzini, M.;
Togliardi, E.;
Daidone, M.;
Gianni, A.;
Salvioni, R.;
Braud, F.

Publication type:

Article

Phase II trial of vorinostat in advanced melanoma.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 526, doi. 10.1007/s10637-014-0066-9

By:

Haas, N.;
Quirt, I.;
Hotte, S.;
McWhirter, E.;
Polintan, R.;
Litwin, S.;
Adams, P.;
McBryan, T.;
Wang, L.;
Martin, L.;
vonMehren, M.;
Alpaugh, R.;
Zweibel, J.;
Oza, A.

Publication type:

Article

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 389, doi. 10.1007/s10637-013-0039-4

By:

Shin, Jae-Sik;
Hong, Seung-Woo;
Moon, Jai-Hee;
Kim, Jin-Sun;
Jung, Kyung-Ah;
Kim, Seung-Mi;
Lee, Dae-Hee;
Kim, InKi;
Yoon, Seon-Joo;
Lee, Chang-Gyu;
Choi, Eun-Kyoung;
Lee, Joo-Young;
Kim, Kyu-pyo;
Hong, Yong;
Lee, Jae-Lyun;
Kim, Bongcheol;
Choi, Eun;
Lee, Jung;
Jin, Dong-Hoon;
Kim, Tae

Publication type:

Article

Successful readministration of trastuzumab after severe immune reactions in two breast cancer patients.

Published in:

2014

By:

Tanz, R.;
Meillan, N.;
Libert, N.;
Magne, N.;
Vedrine, L.;
Chargari, C.

Publication type:

Report

Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 569, doi. 10.1007/s10637-013-0052-7

By:

Bellesoeur, Audrey;
Carton, Edith;
Mir, Olivier;
Groussin, Lionel;
Blanchet, Benoit;
Billemont, Bertrand;
Clerc, Jérôme;
Goldwasser, François

Publication type:

Article

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 500, doi. 10.1007/s10637-013-0060-7

By:

Goldwasser, Francois;
Faivre, Sandrine;
Alexandre, Jerome;
Coronado, Cinthya;
Fernández-García, Eva;
Kahatt, Carmen;
Paramio, Pilar;
Dios, Jorge;
Miguel-Lillo, Bernardo;
Raymond, Eric

Publication type:

Article

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 436, doi. 10.1007/s10637-013-0046-5

By:

Hong, D.;
Kurzrock, R.;
Naing, A.;
Wheler, J.;
Falchook, G.;
Schiffman, J.;
Faulkner, N.;
Pilat, M.;
O'Brien, J.;
LoRusso, P.

Publication type:

Article

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 518, doi. 10.1007/s10637-014-0064-y

By:

von Mehren, Margaret;
Britten, Carolyn;
Pieslor, Peter;
Saville, Wayne;
Vassos, Artemios;
Harris, Sarah;
Galluppi, Gerald;
Darif, Mohamed;
Wainberg, Zev;
Cohen, Roger;
Leong, Stephen

Publication type:

Article

Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 465, doi. 10.1007/s10637-013-0051-8

By:

Fu, Siqing;
Hou, Ming-Mo;
Wheler, Jennifer;
Hong, David;
Naing, Aung;
Tsimberidou, Apostolia;
Janku, Filip;
Zinner, Ralph;
Piha-Paul, Sarina;
Falchook, Gerald;
Kuo, Macus;
Kurzrock, Razelle

Publication type:

Article

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 445, doi. 10.1007/s10637-013-0044-7

By:

Ghamande, Sharad;
Lin, Chia-Chi;
Cho, Daniel;
Shapiro, Geoffrey;
Kwak, Eunice;
Silverman, Michael;
Tseng, Yunlong;
Kuo, Min-Wen;
Mach, Wendy;
Hsu, Shu-Chi;
Coleman, Teresa;
Yang, James;
Cheng, Ann-Lii;
Ghalib, Mohammad;
Chuadhary, Imran;
Goel, Sanjay

Publication type:

Article

CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 400, doi. 10.1007/s10637-013-0043-8

By:

Moon, Chang;
Lee, Seung;
Lee, Ho;
Dung, Le;
Cho, Wha;
Cha, HeeJeong;
Park, Jeong;
Min, Young

Publication type:

Article

SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 412, doi. 10.1007/s10637-013-0041-x

By:

Benbrook, Doris;
Nammalwar, Baskar;
Long, Andrew;
Matsumoto, Hiroyuki;
Singh, Anil;
Bunce, Richard;
Berlin, K.

Publication type:

Article

Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

Published in:

2014

By:

Britten, Carolyn;
Adjei, Alex;
Millham, Robert;
Houk, Brett;
Borzillo, Gary;
Pierce, Kristen;
Wainberg, Zev;
LoRusso, Patricia

Publication type:

Erratum

A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 549, doi. 10.1007/s10637-014-0073-x

By:

Ho, Alan;
Lipson, Brynna;
Sherman, Eric;
Xiao, Han;
Fury, Matthew;
Apollo, Arlyn;
Seetharamu, Nagashree;
Sima, Camelia;
Haque, Sofia;
Lyo, John;
Sales, Roberta;
Cox, Lisa;
Pfister, David

Publication type:

Article

Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 424, doi. 10.1007/s10637-014-0079-4

By:

Radhamani, Suraj;
Bradley, Christopher;
Meehan-Andrews, Terri;
Ihmaid, Saleh;
Al-Rawi, Jasim

Publication type:

Article

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 535, doi. 10.1007/s10637-014-0065-x

By:

Lee, Jeeyun;
Hong, Yong;
Hong, Jung;
Han, Se;
Kim, Tae;
Kang, Hye;
Kim, Kyu-pyo;
Kim, Suk;
Do, In-Gu;
Kim, Kyoung-Mee;
Sohn, Insuk;
Park, Se;
Park, Joon;
Lim, Ho;
Cho, Yong;
Lee, Woo;
Yun, Seong;
Kim, Hee;
Park, Young;
Kang, Won

Publication type:

Article

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 542, doi. 10.1007/s10637-014-0070-0

By:

Ocean, Allyson;
Christos, Paul;
Sparano, Joseph;
Shah, Manish;
Yantiss, Rhonda;
Cheng, Jonathan;
Lin, Juan;
Papetti, Michael;
Matulich, Dan;
Schnoll-Sussman, Felice;
Besanceney-Webler, Christen;
Xiang, Jenny;
Ward, Maureen;
Dilts, Kaili;
Keresztes, Roger;
Holloway, Shannon;
Chen, Eric;
Wright, John;
Lane, Maureen

Publication type:

Article

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 473, doi. 10.1007/s10637-013-0056-3

By:

Komatsu, Yoshito;
Yoshino, Takayuki;
Yamazaki, Kentaro;
Yuki, Satoshi;
Machida, Nozomu;
Sasaki, Takahide;
Hyodo, Ichinosuke;
Yachi, Yutaka;
Onuma, Hiroshi;
Ohtsu, Atsushi

Publication type:

Article

A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 3, p. 561, doi. 10.1007/s10637-014-0075-8

By:

Lee, Jeeyun;
Shin, Sang;
Chung, Ik;
Kim, Tae;
Chun, Hoo-Geun;
Shin, Dong;
Kim, Yeul;
Song, Hong;
Han, Sae-Won;
Kim, Jong;
Kim, Sun;
Choi, Young;
Chung, Hyun

Publication type:

Article